The studies presented herein were driven by reports demonstrating that EGFR mutations are associated with low response rates to PD-1 pathway blockade in non-small cell lung carcinoma (NSCLC) (Gainor et al., 2016). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.